Cargando…

Mobile health-technology integrated care in secondary prevention atrial fibrillation patients: a post-hoc analysis from the mAFA-II randomized clinical trial

AF patients with history of thromboembolic events are at higher risk of thromboembolic recurrences, despite appropriate antithrombotic treatment. We aimed to evaluate the effect of mobile health (mHealth) technology-implemented ‘Atrial fibrillation Better Care’ (ABC) pathway approach (mAFA intervent...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yutao, Romiti, Giulio Francesco, Sagris, Dimitrios, Proietti, Marco, Bonini, Niccolò, Zhang, Hui, Lip, Gregory Y. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326104/
https://www.ncbi.nlm.nih.gov/pubmed/36929347
http://dx.doi.org/10.1007/s11739-023-03249-0
_version_ 1785069358389657600
author Guo, Yutao
Romiti, Giulio Francesco
Sagris, Dimitrios
Proietti, Marco
Bonini, Niccolò
Zhang, Hui
Lip, Gregory Y. H.
author_facet Guo, Yutao
Romiti, Giulio Francesco
Sagris, Dimitrios
Proietti, Marco
Bonini, Niccolò
Zhang, Hui
Lip, Gregory Y. H.
author_sort Guo, Yutao
collection PubMed
description AF patients with history of thromboembolic events are at higher risk of thromboembolic recurrences, despite appropriate antithrombotic treatment. We aimed to evaluate the effect of mobile health (mHealth) technology-implemented ‘Atrial fibrillation Better Care’ (ABC) pathway approach (mAFA intervention) in secondary prevention AF patients. The Mobile Health Technology for Improved Screening and Optimized Integrated Care in AF (mAFA-II) cluster randomized trial enrolled adult AF patients across 40 centers in China. The main outcome was the composite outcome of stroke or thromboembolism, all-cause death, and rehospitalization. Using Inverse Probability of Treatment Weighting (IPTW), we evaluated the effect of the mAFA intervention in patients with and without prior history of thromboembolic events (i.e., ischemic stroke or thromboembolism). Among the 3324 patients enrolled in the trial, 496 (14.9%, mean age: 75.1 ± 11.4 years, 35.9% females) had a previous episode of thromboembolic event. No significant interaction was observed for the effect of mAFA intervention in patients with vs. without history of thromboembolic events [Hazard ratio, (HR): 0.38, 95% confidence interval (CI):0.18–0.80 vs. HR 0.55, 95% CI 0.17–1.76, p for interaction = 0.587); however, a trend towards lower efficacy of mAFA intervention among AF patients in secondary prevention was observed for secondary outcomes, with significant interaction for bleeding events (p = 0.034) and the composite of cardiovascular events (p = 0.015). A mHealth-technology-implemented ABC pathway provided generally consistent reduction of the risk of primary outcome in both primary and secondary prevention AF patients. Secondary prevention patients may require further specific approaches to improve clinical outcomes such as bleeding and cardiovascular events. Trial registration: WHO International Clinical Trials Registry Platform (ICTRP) Registration number ChiCTR-OOC-17014138.
format Online
Article
Text
id pubmed-10326104
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-103261042023-07-08 Mobile health-technology integrated care in secondary prevention atrial fibrillation patients: a post-hoc analysis from the mAFA-II randomized clinical trial Guo, Yutao Romiti, Giulio Francesco Sagris, Dimitrios Proietti, Marco Bonini, Niccolò Zhang, Hui Lip, Gregory Y. H. Intern Emerg Med Im - Original AF patients with history of thromboembolic events are at higher risk of thromboembolic recurrences, despite appropriate antithrombotic treatment. We aimed to evaluate the effect of mobile health (mHealth) technology-implemented ‘Atrial fibrillation Better Care’ (ABC) pathway approach (mAFA intervention) in secondary prevention AF patients. The Mobile Health Technology for Improved Screening and Optimized Integrated Care in AF (mAFA-II) cluster randomized trial enrolled adult AF patients across 40 centers in China. The main outcome was the composite outcome of stroke or thromboembolism, all-cause death, and rehospitalization. Using Inverse Probability of Treatment Weighting (IPTW), we evaluated the effect of the mAFA intervention in patients with and without prior history of thromboembolic events (i.e., ischemic stroke or thromboembolism). Among the 3324 patients enrolled in the trial, 496 (14.9%, mean age: 75.1 ± 11.4 years, 35.9% females) had a previous episode of thromboembolic event. No significant interaction was observed for the effect of mAFA intervention in patients with vs. without history of thromboembolic events [Hazard ratio, (HR): 0.38, 95% confidence interval (CI):0.18–0.80 vs. HR 0.55, 95% CI 0.17–1.76, p for interaction = 0.587); however, a trend towards lower efficacy of mAFA intervention among AF patients in secondary prevention was observed for secondary outcomes, with significant interaction for bleeding events (p = 0.034) and the composite of cardiovascular events (p = 0.015). A mHealth-technology-implemented ABC pathway provided generally consistent reduction of the risk of primary outcome in both primary and secondary prevention AF patients. Secondary prevention patients may require further specific approaches to improve clinical outcomes such as bleeding and cardiovascular events. Trial registration: WHO International Clinical Trials Registry Platform (ICTRP) Registration number ChiCTR-OOC-17014138. Springer International Publishing 2023-03-16 2023 /pmc/articles/PMC10326104/ /pubmed/36929347 http://dx.doi.org/10.1007/s11739-023-03249-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Im - Original
Guo, Yutao
Romiti, Giulio Francesco
Sagris, Dimitrios
Proietti, Marco
Bonini, Niccolò
Zhang, Hui
Lip, Gregory Y. H.
Mobile health-technology integrated care in secondary prevention atrial fibrillation patients: a post-hoc analysis from the mAFA-II randomized clinical trial
title Mobile health-technology integrated care in secondary prevention atrial fibrillation patients: a post-hoc analysis from the mAFA-II randomized clinical trial
title_full Mobile health-technology integrated care in secondary prevention atrial fibrillation patients: a post-hoc analysis from the mAFA-II randomized clinical trial
title_fullStr Mobile health-technology integrated care in secondary prevention atrial fibrillation patients: a post-hoc analysis from the mAFA-II randomized clinical trial
title_full_unstemmed Mobile health-technology integrated care in secondary prevention atrial fibrillation patients: a post-hoc analysis from the mAFA-II randomized clinical trial
title_short Mobile health-technology integrated care in secondary prevention atrial fibrillation patients: a post-hoc analysis from the mAFA-II randomized clinical trial
title_sort mobile health-technology integrated care in secondary prevention atrial fibrillation patients: a post-hoc analysis from the mafa-ii randomized clinical trial
topic Im - Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326104/
https://www.ncbi.nlm.nih.gov/pubmed/36929347
http://dx.doi.org/10.1007/s11739-023-03249-0
work_keys_str_mv AT guoyutao mobilehealthtechnologyintegratedcareinsecondarypreventionatrialfibrillationpatientsaposthocanalysisfromthemafaiirandomizedclinicaltrial
AT romitigiuliofrancesco mobilehealthtechnologyintegratedcareinsecondarypreventionatrialfibrillationpatientsaposthocanalysisfromthemafaiirandomizedclinicaltrial
AT sagrisdimitrios mobilehealthtechnologyintegratedcareinsecondarypreventionatrialfibrillationpatientsaposthocanalysisfromthemafaiirandomizedclinicaltrial
AT proiettimarco mobilehealthtechnologyintegratedcareinsecondarypreventionatrialfibrillationpatientsaposthocanalysisfromthemafaiirandomizedclinicaltrial
AT bonininiccolo mobilehealthtechnologyintegratedcareinsecondarypreventionatrialfibrillationpatientsaposthocanalysisfromthemafaiirandomizedclinicaltrial
AT zhanghui mobilehealthtechnologyintegratedcareinsecondarypreventionatrialfibrillationpatientsaposthocanalysisfromthemafaiirandomizedclinicaltrial
AT lipgregoryyh mobilehealthtechnologyintegratedcareinsecondarypreventionatrialfibrillationpatientsaposthocanalysisfromthemafaiirandomizedclinicaltrial
AT mobilehealthtechnologyintegratedcareinsecondarypreventionatrialfibrillationpatientsaposthocanalysisfromthemafaiirandomizedclinicaltrial